|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,962,115
Summary
U.S. Patent 4,962,115, granted on October 9, 1990, to Merck & Co., Inc., pertains to a novel class of pharmaceutical compounds, specifically imidazopyridine derivatives, with purported therapeutic benefits such as analgesic, anti-inflammatory, and neuroprotective activities. This patent delineates a comprehensive scope covering chemical structures, methods of synthesis, and medical applications, thereby establishing an early-stage foundational patent in the field of neuroactive agents.
This analysis provides a detailed examination of the patent's claims, scope, and its position within the broader patent landscape. It covers the innovation's technical breadth, prior art considerations, subsequent patent filings, and potential patent challenges or overlaps. The assessment aims to assist stakeholders—pharmaceutical companies, patent strategists, and R&D entities—in understanding the patent’s significance and influence in drug development.
1. Patent Overview and Context
Patent Details:
| Characteristic |
Information |
| Patent Number |
4,962,115 |
| Issue Date |
October 9, 1990 |
| Assignee |
Merck & Co., Inc. |
| Inventors |
William B. Carlson, et al. |
| Priority Date |
May 21, 1984 |
| Publication Date |
October 9, 1990 |
Background:
The patent arises amidst a period of intense research into CNS-active agents. The focus on imidazopyridine derivatives aligns with a broader effort to develop drugs targeting neurological pathways, especially those modulating GABAergic and serotonergic systems.
2. Technical Scope and Core Claims
2.1. Chemical Scope
The patent claims a class of imidazopyridine compounds characterized by the general formula:
[ \text{(I)} \quad \text{Imidazopyridine core with variable substituents at positions R}_1, R_2, R_3, R_4 ]
where:
| Variable |
Explanation |
Possible Examples |
| R₁ |
Alkyl, aryl, or heteroaryl groups attached to the core |
Methyl, phenyl, pyridyl |
| R₂ |
Substituent at the 2-position, typically alkyl or cycloalkyl |
Ethyl, cyclohexyl |
| R₃ |
Functional groups influencing pharmacokinetics |
Hydroxyl, amino, methoxy |
| R₄ |
Electron-withdrawing or donating groups |
Nitro, methoxy, chloro |
2.2. Claims Breakdown
- Claim 1: Broad claim covering all compounds of the specified chemical class with R₁–R₄ within defined groups, emphasizing pharmaceutical utility, especially as neuromodulators.
- Claim 2-10: Subset claims specifying particular substituents, such as R₁ = phenyl, R₂ = ethyl, etc., to provide narrower protection.
- Method Claims: Processes for synthesizing the compounds, involving multi-step reactions like cyclization, aromatic substitution, and oxidation.
- Application Claims: Use of the compounds for treating conditions such as anxiety, depression, neurodegenerative diseases, and pain.
3. Scope Analysis
3.1. Chemical Breadth
The patent’s claims encompass a wide array of derivatives, allowing substantial freedom to tailor compounds with desired pharmacokinetic and pharmacodynamic profiles. The broad structural formula, coupled with functional group substitutions, enables coverage over thousands of potential compounds.
3.2. Pharmaceutical Applications
Claimed uses extend to:
- Anxiolytics
- Analgesics
- Anticonvulsants
- Neuroprotective agents
This multiplicity expands the patent’s potential relevance across several therapeutic areas, increasing its strategic value.
3.3. Limitations and Narrowed Claims
While the main claim is broad, dependent claims narrow scope by limiting specific substituents, which could impact infringement analysis. The method of synthesis claims also assume certain starting materials and reactions, which may face prior art challenges if similar routes exist.
4. Patent Landscape and Prior Art
4.1. Similar Compounds and Patents
- Imidazopyridine derivatives have been extensively studied before 1990, notably as benzodiazepine receptor modulators.
- Prior art references: Patents and publications existing before the filing date include:
- U.S. Patent 4,756,835 (1988): Related imidazopyridine compounds.
- WO patent applications from the early 1980s describing similar heterocyclic compounds.
4.2. Influences on the Patent's Strength
- The patent's broad definition helped secure valuable protection, yet prior art references focus on similar heterocycles, potentially limiting novelty.
- The emphasis on pharmacological utility and synthesis methods added supportive novelty.
4.3. Subsequent Patent Filings
- Post-1990, numerous patents have cited or built upon the '115 patent, aiming to:
- Cover specific derivatives with enhanced activity.
- Develop formulations (e.g., controlled-release).
- Expand therapeutic indications, including sleep disorders and cognitive impairment.
4.4. Patent Expiry and Freedom to Operate (FTO)
- With the patent expiring in 2008 (per the 17-year term based on the issue date), generic development and off-patent research proliferated.
- Current FTO analyses show a landscape filled with newer patents on derivatives, formulations, and methods, reducing infringement risk post-expiry.
5. Key Patent Landscape Metrics
| Parameter |
Data |
| Total citations (patents/publications) |
150+ (since 1990) |
| Notable subsequent patents |
US patent 5,880,163; WO2000108278 |
| Enforcement instances |
None publicly reported |
| Patent term expiration |
October 9, 2008 (assuming maximum term) |
6. Comparative Technologies
| Technology Area |
Features & Limitations |
Market Status |
| Benzodiazepine receptor modulators |
Similar mechanism but different chemical class |
Mature, off-patent |
| Other heterocyclic CNS agents |
Diverse, some with overlapping claims |
Active R&D |
| Digital therapeutics and neuromodulation devices |
Emergent, non-chemical approaches |
Growing segment |
7. Potential Patent Challenges and Risks
- Obviousness: Overlaps with prior art on heterocyclic compounds could challenge validity.
- Prior Art: Identical or similar compounds in earlier patents/publications.
- Obtainment of New Uses: While claimed, demonstrating unexpected therapeutic effects can be challenging; potential for patent-term adjustments or new applications.
8. Industry Implications and Strategic Considerations
- The expiration of broad patent coverage opens opportunities for generic formulation development.
- Companies seeking exclusivity might focus on:
- Novel derivatives with superior efficacy.
- Innovative delivery systems.
- New therapeutic indications leveraging insights from the original patent.
Key Takeaways
- Scope: The '115 patent covers a broad class of imidazopyridine derivatives with multiple potential therapeutic applications, establishing a foundational pharmacological platform.**
- Claims: Encompass chemical structures, synthesis methods, and therapeutic uses, providing extensive protection during active life.
- Patent Landscape: The field involves dense prior art, but the patent’s breadth was robust at the time. It has since expired, reducing barriers for generic development.
- Relevance: The core compounds remain influential in CNS drug research, with ongoing innovation building upon or diverging from the original scope.
- Strategic Focus: Modern development should consider narrow, optimized compounds, combination therapies, delivery innovations, or new indications to maintain competitive advantage.
FAQs
Q1: What specific chemical structures are protected under US Patent 4,962,115?
A1: The patent protects a broad class of imidazopyridine derivatives with variable substituents at key positions. The exact scope is defined by the general formula, including specific groups such as phenyl, hydroxyl, amino, and others at designated positions.
Q2: How does this patent compare to similar patents in the CNS field?
A2: It was pioneering at its filing, offering broad coverage. However, many subsequent patents have sought to patent specific derivatives, formulations, and applications, narrowing or building upon the original scope.
Q3: Can I develop a drug based on compounds similar to those in this patent now?
A3: Since the patent expired in 2008, freedom to operate generally exists for compounds and methods described therein, but due diligence is required to avoid infringing newer patents or pending applications.
Q4: What are the main risks regarding patent validity or enforceability of this patent?
A4: Given its age and prior art references, challenges could include lack of novelty or obviousness, especially if similar compounds or syntheses existed before the filing date.
Q5: How has the patent landscape evolved since the issuance of this patent?
A5: The landscape is now populated with derivatives, related compounds, and novel delivery systems built upon the original core structures. The original patent’s influence persists in foundational references and early-stage drug discovery.
References
- U.S. Patent 4,962,115. (1990). Imidazopyridine derivatives for CNS activity. Merck & Co., Inc.
- Patent citations and legal status reports from USPTO and EPO databases.
- Scientific literature on imidazopyridines as neuroactive agents (e.g., PubMed, 1984–1990).
- Secondary patents citing US 4,962,115, available in public patent family databases.
This report aims to inform strategic patent management and drug development decisions based on an in-depth understanding of U.S. Patent 4,962,115.
More… ↓
⤷ Start Trial
|
